Fenwick Represents Dermira in $169 Million Public Offering of Common Stock

Fenwick & West represented Dermira, Inc. (Nasdaq: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to patients living with chronic skin conditions, in its underwritten public offering of 12,754,717 shares of common stock at a public offering price of $13.25 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,471,698 shares of common stock.

Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim Securities acted as book-runners for the offering. Needham & Company and H.C. Wainwright & Co. acted as co-managers.

The Fenwick transaction team included corporate lawyers Michael Brown, Kat Duncan, Jen Hitchcock, Jenna Hsieh and Meredith Evancie.